AI assistant
REPLIGEN CORP — Director's Dealing 2020
Mar 3, 2020
30826_dirs_2020-03-02_182cf643-c3e8-44e6-b432-a831de71ef34.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2020-02-27
Reporting Person: Hunt Anthony (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-27 | Common Stock | A | 18583 | $0.00 | Acquired | 244731 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-27 | Stock Option (Right to Buy) | $86.10 | A | 18128 | Disposed | 2030-02-27 | Common Stock (18128) | Direct |
Footnotes
F1: Mr. Hunt was awarded 18,583 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: One third of the stock options will vest and become exercisable annually on February 27, 2021, February 27, 2022 and February 27, 2023.